에 대한 최신 뉴스 Aurora Innovation (NASDAQ:AUR) 주식

Aurora Innovation

Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, an advanced and scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.

Equities

Large Cap

News

Topics

Movers

AKAM

AXON

COIN

EPAM

HOOD

RDDT

TWLO

지난주 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다. 아카마이, 액손, 트윌리오, 이팸 시스템즈, 누 홀딩스, 오로라, 코인베이스, 다비타, 로빈후드, 레딧

트윌리오, 코인베이스, 레딧 등 지난주 급락한 대형주 10종목 (2월 17일~21일)

Trading Ideas

AAPL

ABNB

BABA

BROS

DKNG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INTC

MNDY

SMCI

이들 12개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 힘스 앤 허스 헬스(NYSE:HIMS)의 주식은 지난주 42.12% 상승했다. 이는 슈퍼볼 광고 이후의 모멘텀에 힘입어 상승한 것으로 보인다.

슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)

CTTAF

FTAI

ITCI

NVDA

RPRX

SNAP

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가가 회사가 예상보다 나은 1분기 재무결과를 발표한 후 27.97% 상승했다.

월그린스, 마이크론 및 델타 항공은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 6일-10일)

Aurora Innovation, Inc. - Class A Common Stock

Aurora Innovation Inc

Aura Biosciences Inc

AURORA ACQUISITION CORP CL A

Auri Inc

AURUM MEGAMETALS CORP by Aurum Megametals Corp.

Aurum Megametals Corp

Aurion Biotech Inc

Aurora - United States Dollar

AURELIUS MINERALS INC by Aurelius Minerals Inc.

Aurelius Minerals Inc

Attune RTD

Aurwest Resources Corp

NUO THERAPEUTICS INC NEW by Nuo Therapeutics, Inc.

Nuo Therapeutics Inc

Aurory

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares are trading lower Thursday after the company's Athena lander reportedly faced technical issues during its <a href="https://www.benzinga.com/content/44142027/intuitive-machines-march-6-is-a-pivotal-day-for-lunar-economy">lunar landing attempt.</a>
What To Know: The Athena lander, part of NASA's Commercial Lunar Payload Services initiative, aimed to touch down approximately 100 miles from the lunar south pole. However, telemetry indicated that the lander's engine was still running past the scheduled landing time, suggesting it was hovering above the surface. Intuitive Machines later issued a brief confirmation that Athena is on the lunar surface and receiving solar power, but the lander's exact position remains uncertain.
The Houston-based company's latest lunar mission follows a prior attempt nearly a year ago with its Odysseus lander. That mission ended with a hard touchdown due to a faulty laser altimeter, causing the lander to topple over and rendering many of its onboard experiments inoperable. This time, Athena carried 11 payloads and scientific instruments intended to gather data near the lunar south pole, a region viewed as a critical target for future lunar exploration due to the presence of subsurface water ice.
The company ended its live stream shortly after announcing the landing and plans to provide further updates at a scheduled press conference. Intuitive Machines' stock, which has more than doubled over the past year, fell over 20% in afternoon trading as investors reacted to the uncertainty surrounding the lander's condition.
LUNR Price Action: Intuitive shares were down 18.5% at $11.51 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06134600/Screenshot-2025-03-06-at-13.45.40-1024x530.png" alt="" class="wp-image-812823" style="width:412px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06134600/Screenshot-2025-03-06-at-13.45.40-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06134600/Screenshot-2025-03-06-at-13.45.40-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06134600/Screenshot-2025-03-06-at-13.45.40-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06134600/Screenshot-2025-03-06-at-13.45.40.png 1525w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44172028/trade-turmoil-oil-slides-whats-driving-markets-thursday">Trade Turmoil, Oil Slides: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image via Shutterstock.

LUNR

Intuitive Machines Stock Falls After Uncertain Athena Moon Landing

The energy sector is facing heightened investor scrutiny as recent developments have added uncertainty to oil markets. 
A combination of rising U.S. crude inventories, geopolitical tensions and trade concerns has triggered volatility in oil prices, leading to mixed reactions across energy-related stocks and ETFs. With these changes in play, investors are closely watching <a href="https://www.benzinga.com/etfs">oil-focused ETFs</a> to gauge their exposure and potential risks.
<h1 class="wp-block-heading">ETFs To Watch Amid These Developments</h1>
For investors looking to navigate these shifting dynamics, several energy-focused ETFs offer exposure to key industry players:
Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>): This ETF tracks large-cap energy stocks, including major oil and gas giants like ExxonMobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>). Given recent market pressures, XLE has experienced fluctuations, but it remains a popular choice for those seeking broad exposure to the sector, with an expense ratio of 0.09%.
Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>): Offering a more diversified portfolio, VDE covers both upstream and downstream oil and gas companies, providing investors with a balanced approach amid market uncertainty. Apart from Exxon and Chevron, the fund also allocates a significant weightage to companies like ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>). The recent volatility in the oil sector has taken most of the stocks in the ETF for a ride.
United States Natural Gas Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>): Unlike oil-focused ETFs, UNG provides investors with exposure to natural gas futures. This ETF is particularly relevant for those looking to diversify within the energy sector, as natural gas prices are influenced by different factors than crude oil, including weather patterns, production levels and storage data. Given the increasing reliance on natural gas for power generation and heating, UNG offers a distinct alternative for energy-focused investors.
Also Read: <a href="https://www.benzinga.com/content/44164489/2-energy-stocks-to-play-both-sides-of-tariff-uncertainty">2 Energy Stocks to Play Both Sides of Tariff Uncertainty</a>
<h1 class="wp-block-heading">Oil Prices Plummet, Consumer Sentiment Damp</h1>
Oil prices recently hit a six-month low as <a href="https://www.benzinga.com/news/25/03/44150023/why-exxon-mobil-xom-stock-hit-a-new-52-week-low-today">U.S. crude stockpiles increased </a>by 3.6 million barrels as of March 5. This unexpected rise in supply has weighed heavily on energy stocks, including major players such as ExxonMobil. 
As one of the largest integrated oil and gas companies, Exxon is particularly vulnerable to declining crude prices, which directly impact its upstream profits. Lower prices also squeeze refining margins, making it more difficult for companies to offset losses through downstream operations. Thus, ETFs with significant allocations in Exxon, such as XLE and VDE stand to be affected by oil price slips.
Adding to the pressure, OPEC+ has confirmed its plan to roll back production cuts in April, fueling concerns about a potential supply glut. This decision has further dampened investor sentiment in the energy sector.
Moreover, the Trump administration is considering a strategy to halt and inspect Iranian oil tankers at sea, a move aimed at curbing Tehran's oil revenue and its potential links to nuclear proliferation. If implemented, these inspections could delay crude deliveries, leading to supply chain disruptions. 
Iran has previously retaliated against such measures by seizing foreign vessels, raising concerns about further escalation in maritime tensions.
<a href="https://www.benzinga.com/25/01/42922934/oil-stocks-rally-on-anticipation-of-stricter-russian-sanctions-heres-how-etfs-are-reacting">Trade tensions have resurfaced</a> with the Trump administration imposing import tariffs of 25% on Mexico and Canada and an additional 10% on China. Given that Canada is the top supplier of crude oil to the U.S., these tariffs could have significant implications for energy trade. A third of all U.S. crude imports come from Mexico, further amplifying concerns about the impact of protectionist policies on the energy sector.
With oil prices experiencing turbulence, geopolitical tensions rising and trade policies shifting, energy-focused ETFs are in the spotlight. Whether investors see the current downturn as a buying opportunity or a reason to tread cautiously, it would be prudent to stay informed about market trends and ETF holdings.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44171147/spy-etf-has-ruled-for-decades-but-is-it-still-the-best-bet">SPY ETF Has Ruled For Decades, But Is It Still The Best Bet?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

Global

ETFs

Geopolitics, Tariffs, Supply Glut: What's Next For Oil ETFs?

Deep-pocketed investors have adopted a bearish approach towards Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Dollar Gen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $201,510, and 2 are calls, amounting to $69,050.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $85.0 for Dollar Gen over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Dollar Gen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Dollar Gen's substantial trades, within a strike price spectrum from $60.0 to $85.0 over the preceding 30 days.
<h3>Dollar Gen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741288648_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.85</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$75.00</td>
<td>$43.5K</td>
<td>648</td>
<td align="right">167</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$36.0K</td>
<td>1.7K</td>
<td align="right">66</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.7</td>
<td>$17.3</td>
<td>$17.7</td>
<td>$85.00</td>
<td>$35.4K</td>
<td>1.4K</td>
<td align="right">24</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.75</td>
<td>$60.00</td>
<td>$35.2K</td>
<td>749</td>
<td align="right">341</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$34.9K</td>
<td>1.7K</td>
<td align="right">132</td>
</tr>
</tbody>
</table>

<h3>About Dollar Gen</h3>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
Following our analysis of the options activities associated with Dollar Gen, we pivot to a closer look at the company's own performance.
<h3>Current Position of Dollar Gen</h3>
<ul>
<li>Trading volume stands at 1,482,950, with DG's price up by 2.54%, positioned at $75.57.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Professional Analyst Ratings for Dollar Gen</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $86.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Dollar Gen, maintaining a target price of $85. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Dollar Gen, which currently sits at a price target of $95. 
&#x2A; An analyst from Deutsche Bank downgraded its action to Hold with a price target of $80. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Dollar Gen, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Smart Money Is Betting Big In Dollar Gen Options

Deep-pocketed investors have adopted a bullish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 40% bearish. Among these notable options, 5 are puts, totaling $279,455, and 10 are calls, amounting to $885,741.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $150.0 for Cava Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $60.0 to $150.0, over the past month.
<h3>Cava Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741288643_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$33.35</td>
<td>$32.55</td>
<td>$33.35</td>
<td>$60.00</td>
<td>$226.7K</td>
<td align="right">777</td>
<td align="right">68</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$37.7</td>
<td>$36.65</td>
<td>$37.7</td>
<td>$65.00</td>
<td>$188.5K</td>
<td align="right">13</td>
<td align="right">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$32.65</td>
<td>$32.15</td>
<td>$32.65</td>
<td>$75.00</td>
<td>$159.9K</td>
<td align="right">108</td>
<td align="right">49</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$95.00</td>
<td>$87.5K</td>
<td align="right">476</td>
<td align="right">50</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$26.5</td>
<td>$25.85</td>
<td>$26.2</td>
<td>$110.00</td>
<td>$78.6K</td>
<td align="right">800</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.
<h3>Cava Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,312,033, with CAVA's price down by -4.63%, positioned at $82.74.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 82 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cava Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $121.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Hold rating for Cava Group, targeting a price of $100. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Cava Group with a target price of $104. 
&#x2A; Reflecting concerns, an analyst from Wedbush lowers its rating to Outperform with a new price target of $150. 
&#x2A; An analyst from Piper Sandler upgraded its action to Overweight with a price target of $115. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Cava Group, targeting a price of $140. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cava Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CAVA

Unpacking the Latest Options Trading Trends in Cava Group

Deep-pocketed investors have adopted a bullish approach towards AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AZO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for AutoZone. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 8% bearish. Among these notable options, 5 are puts, totaling $332,750, and 7 are calls, amounting to $324,653.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2800.0 to $4000.0 for AutoZone over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AutoZone's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AutoZone's whale trades within a strike price range from $2800.0 to $4000.0 in the last 30 days. 
<h3>AutoZone 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741288638_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$103.0</td>
<td>$100.0</td>
<td>$100.0</td>
<td>$3600.00</td>
<td>$100.0K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$474.0</td>
<td>$471.0</td>
<td>$471.0</td>
<td>$4000.00</td>
<td>$94.2K</td>
<td align="right">3</td>
<td align="right">2</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$841.7</td>
<td>$827.5</td>
<td>$840.0</td>
<td>$2800.00</td>
<td>$84.0K</td>
<td align="right">8</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$757.0</td>
<td>$744.2</td>
<td>$750.0</td>
<td>$2900.00</td>
<td>$75.0K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>AZO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$64.0</td>
<td>$55.1</td>
<td>$59.5</td>
<td>$3500.00</td>
<td>$59.5K</td>
<td align="right">5</td>
<td align="right">13</td>
</tr>
</tbody>
</table>

<h3>About AutoZone</h3>
AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates more than 6,400 stores domestically, serving both the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and in some instances, installation. The company also operates internationally, with 800 stores in Mexico and more than 100 in Brazil.
<h3>Current Position of AutoZone</h3>
<ul>
<li>With a volume of 85,033, the price of AZO is up 0.14% at $3561.03. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About AutoZone</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $3718.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Neutral rating on AutoZone, maintaining a target price of $3700. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for AutoZone, targeting a price of $3850. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $3700. 
&#x2A; An analyst from DA Davidson persists with their Neutral rating on AutoZone, maintaining a target price of $3500. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on AutoZone, maintaining a target price of $3841. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AutoZone, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding AutoZone's Options Activity: What's the Big Picture?

The National Institute for Health and Care Excellence (NICE) has reaffirmed its stance against recommending Alzheimer&#8217;s treatments donanemab and lecanemab for NHS use, citing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">insufficient cost-effectiveness</a>.
Despite additional evidence submitted by manufacturers, the independent appraisal committee <a target="_blank" href="https://www.nice.org.uk/news/articles/second-consultation-launched-on-nhs-funding-for-alzheimer-s-treatments" rel="noreferrer noopener">concluded</a> that the treatments do not provide enough benefit to justify their significant cost.
NICE first raised concerns about these treatments last year, determining that their clinical benefits did not outweigh the financial burden they would place on the NHS.
Read Next: <a target="_blank" href="https://www.benzinga.com/25/03/44171941/denali-therapeutics-ends-als-trial-extension-analyst-stays-optimistic-despite-trial-setback" rel="noreferrer noopener">Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback</a>
Although the U.K.&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) approved Eli Lilly&#8217;s Kisunla (donanemab) in October, NICE <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41498770/eli-lilly-alzheimers-drug-faces-tough-road-in-uk-price-watchdog-nice-says-donanemab-is-not-cost-effe" rel="noreferrer noopener">refused&nbsp;to cover it</a>.
The agency ruled that the cost of providing donanemab balanced against the relatively small benefit cannot currently be considered good value for the taxpayer.
In August, MHRA approved Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514109/biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimburs" rel="noreferrer noopener">Leqembi (lecanemab)</a>.
Despite the approval, NICE said in its guidance draft,&#8221;&nbsp;benefits of the new Alzheimer&#8217;s drug lecanemab are too small to justify the costs.&#8221;
Following a request for further data, the latest assessment has reinforced that donanemab and lecanemab remain economically unviable for NHS funding.
&#8220;Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab,&#8221; the agency says in its statement.
Stakeholders are encouraged to contribute their perspectives before the consultation period closes on March 27, 2025.
A third committee meeting will review all responses and additional analyses before NICE issues its final recommendations.
Price Action: At the last check on Thursday, BIIB stock was up 1.50% at $145.92, and LLY stock was down 2.82% at $903.84.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44170118/meet-magic-apron-home-depot-launches-generative-ai-tool-to-enhance-spring-shopping" target="_blank" rel="noreferrer noopener">Meet Magic Apron: Home Depot Launches Generative AI Tool To Enhance Spring Shopping</a></li>
</ul>
Photo via Shutterstock

Biotech

Government

Health Care

General

BIIB

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding

Despite Dogecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) lackluster performance, whale investors are aggressively accumulating DOGE ahead of <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44125213/white-house-crypto-summit-to-feature-roundtable-with-industry-leaders-including-michael-saylor">Friday&#8217;s crypto summit</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2010</td>
<td>$29.8 billion</td>
<td>-0.5%</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001317</td>
<td>$7.8 billion</td>
<td>+0.3%</td>
<td>-9.4%</td>
</tr>
<tr>
<td>PEPE (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.056803 &nbsp;</td>
<td>$2.9 billion</td>
<td>-2.7%</td>
<td>-18.8%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: In an X <a href="https://x.com/ali_charts/status/1897396450528809329">post</a> on Thursday, Crypto chart analyst Ali Martinez highlighted that DOGE is trading within an ascending parallel channel. If the $0.16 support level holds, a rally toward the mid-channel at $2.74 or even the upper boundary at $6.24 remains possible.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> remains within an ascending parallel channel. As long as the lower boundary at $0.16 holds, a rebound toward the mid-channel at $2.74 or even the upper boundary at $6.24 remains a probability! <a href="https://t.co/L0p9ePH5ZV">pic.twitter.com/L0p9ePH5ZV</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1897396450528809329?ref_src=twsrc%5Etfw">March 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In another <a href="https://x.com/ali_charts/status/1897582425611604128">tweet</a>, Martinez warned that if DOGE fails to hold this level, it could crash significantly. 
DOGE has tended to rebound from this channel since 2014 towards the upward resistance trend line. 
A break below $0.19 could trigger a sharp correction toward $0.015.
Statistics: Martinez <a href="https://x.com/ali_charts/status/1897700957103837293">cited</a> Santiment data to show whales purchased 150 million DOGE in the last 72 hours.
Coinglass data shows Dogecoin liquidations in the past 24 hours stood at $6.5 million, while open interest increased 2.4% to $1.8 billion. DOGE Derivatives trading volume expanded 12.9% to $3.08 billion.
What's Next: With rising whale activity, increasing open interest, and the upcoming White House event, DOGE could be setting up for a major move—but whether that's a breakout or breakdown depends on key support levels.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44145377/dogecoin-indicators-flash-oversold-conditions-is-it-time-to-accumulate">Dogecoin Indicators Flash Oversold Conditions: Is It Time To Accumulate?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Whales Accumulating 150 Million DOGE Despite Price Drop: What Do They Know?

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Buy and maintains $28 price target.

Price Target

Reiteration

Analyst Ratings

PHAT

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

CLSD

Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

10 analysts have shared their evaluations of Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Northern Trust, revealing an average target of $118.5, a high estimate of $136.00, and a low estimate of $102.00. Marking an increase of 5.07%, the current average surpasses the previous average price target of $112.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1741287787_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Northern Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$114.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$122.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$127.00</td>
<td>$103.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Northern Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Northern Trust compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Northern Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Northern Trust's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Northern Trust analyst ratings.</a>
<h2>About Northern Trust</h2>
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of September 2024, Northern Trust had assets under custody or administration of $17.4 trillion and assets under management of $1.6 trillion.
<h3>Key Indicators: Northern Trust's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Northern Trust displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 26.81%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Northern Trust's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 22.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.76%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Northern Trust's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.29%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.12.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRS

10 Analysts Assess Northern Trust: What You Need To Know

15 analysts have expressed a variety of opinions on Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.07, along with a high estimate of $68.00 and a low estimate of $21.00. Witnessing a positive shift, the current average has risen by 38.89% from the previous average price target of $26.69.
<img src="https://www.benzinga.com/files/images/story/2025/1741287773_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Hims &amp; Hers Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Sell</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$42.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims &amp; Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hims &amp; Hers Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hims &amp; Hers Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hims &amp; Hers Health analyst ratings.</a>
<h2>Delving into Hims &amp; Hers Health's Background</h2>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Understanding the Numbers: Hims &amp; Hers Health's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Hims &amp; Hers Health's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 95.09%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims &amp; Hers Health's net margin excels beyond industry benchmarks, reaching 5.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hims &amp; Hers Health's ROE stands out, surpassing industry averages. With an impressive ROE of 5.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hims &amp; Hers Health's ROA stands out, surpassing industry averages. With an impressive ROA of 3.97%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 15 Analyst Projections For Hims & Hers Health

HC Wainwright &amp; Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

During the last three months, 10 analysts shared their evaluations of Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.7, along with a high estimate of $10.00 and a low estimate of $5.00. Experiencing a 19.88% decline, the current average is now lower than the previous average price target of $9.61. 
<img src="https://www.benzinga.com/files/images/story/2025/1741287758_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Health Catalyst's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$9.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Health Catalyst. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Health Catalyst compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Health Catalyst's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Health Catalyst's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HCAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Health Catalyst analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Health Catalyst's Background</h2>
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
<h3>Financial Insights: Health Catalyst</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Health Catalyst's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 6.02%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Health Catalyst's net margin is impressive, surpassing industry averages. With a net margin of -25.97%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Health Catalyst's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Health Catalyst's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Health Catalyst's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCAT

10 Analysts Have This To Say About Health Catalyst

Ratings for Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Plug Power, revealing an average target of $1.81, a high estimate of $3.00, and a low estimate of $1.00. This current average has decreased by 26.72% from the previous average price target of $2.47. 
<img src="https://www.benzinga.com/files/images/story/2025/1741287748_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Plug Power by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur Sitbon</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.60</td>
<td>$1.75</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.25</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Ryan Pfingst</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.10</td>
<td>$1.40</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.80</td>
<td>$2.50</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$1.40</td>
<td>$1.60</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Tom Curran</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$1.00</td>
<td>-</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Plug Power. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Plug Power compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Plug Power's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PLUG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Plug Power analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Plug Power Better</h2>
Plug Power is building an end-to-end green hydrogen ecosystem-from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
<h3>Financial Milestones: Plug Power's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Plug Power's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -13.81%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Plug Power's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -697.46%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Plug Power's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -56.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Plug Power's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -32.07%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLUG

10 Analysts Assess Plug Power: What You Need To Know

Analysts' ratings for VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.75, along with a high estimate of $5.75 and a low estimate of $5.75. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2025/1741287737_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive VYNE Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.75</td>
<td>$5.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VYNE Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VYNE Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for VYNE Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of VYNE Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VYNE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on VYNE Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About VYNE Therapeutics</h2>
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
<h3>Unraveling the Financial Story of VYNE Therapeutics</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: VYNE Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.14%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: VYNE Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10047.11%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): VYNE Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -17.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -14.93%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.0, VYNE Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VYNE

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Across the recent three months, 17 analysts have shared their insights on Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Kroger and provided 12-month price targets. The average target is $69.06, accompanied by a high estimate of $75.00 and a low estimate of $61.00. This upward trend is apparent, with the current average reflecting a 2.75% increase from the previous average price target of $67.21.
<img src="https://www.benzinga.com/files/images/story/2025/1741287728_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kroger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Leah Jordan</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$61.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Kroger. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kroger compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Kroger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Kroger's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kroger analyst ratings.</a>
<h2>Unveiling the Story Behind Kroger</h2>
Kroger is one of the largest grocery retailers in the United States with more than 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The firm also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
<h3>Financial Milestones: Kroger's Journey</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Kroger's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -0.95%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Kroger's net margin excels beyond industry benchmarks, reaching 1.84%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Kroger's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.86%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Kroger's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Kroger's debt-to-equity ratio surpasses industry norms, standing at 2.31. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Kroger: 17 Analysts Share Their Views

Investors with a lot of money to spend have taken a bullish stance on Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WDC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Western Digital.
This isn't normal.
The overall sentiment of these big-money traders is split between 80% bullish and 13%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $491,200, and 4 are calls, for a total amount of $126,026.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $42.5 to $50.0 for Western Digital over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Western Digital's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Western Digital's whale activity within a strike price range from $42.5 to $50.0 in the last 30 days. 
<h3>Western Digital Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741287722_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$76.4K</td>
<td align="right">1</td>
<td>1.8K</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$72.4K</td>
<td align="right">1</td>
<td>1.8K</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$54.4K</td>
<td align="right">1</td>
<td>209</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.35</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$53.2K</td>
<td align="right">1</td>
<td>441</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$42.50</td>
<td>$44.0K</td>
<td align="right">1</td>
<td>902</td>
</tr>
</tbody>
</table>

<h3>About Western Digital</h3>
Western Digital is a leading, vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly with, Western Digital and Seagate being the two largest players. Western Digital designs and manufacturers its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
Having examined the options trading patterns of Western Digital, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Western Digital Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,941,931, the WDC's price is down by -4.84%, now at $42.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 49 days.</li>
</ul>
<h3>Professional Analyst Ratings for Western Digital</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $86.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Western Digital, which currently sits at a price target of $75. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $95. 
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $95. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $95. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Western Digital with a target price of $74. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Western Digital, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Western Digital Unusual Options Activity

Financial giants have made a conspicuous bearish move on EQT. Our analysis of options history for EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) revealed 15 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $1,185,722, and 6 were calls, valued at $243,408.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $33.0 to $50.0 for EQT during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of EQT stands at 2011.0, with a total volume reaching 7,840.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in EQT, situated within the strike price corridor from $33.0 to $50.0, throughout the last 30 days.
<h3>EQT Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741287716_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.02</td>
<td>$1.97</td>
<td>$2.0</td>
<td>$45.00</td>
<td>$332.6K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.5</td>
<td>$1.39</td>
<td>$1.5</td>
<td>$33.00</td>
<td>$316.8K</td>
<td>2.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$45.00</td>
<td>$293.4K</td>
<td>4.2K</td>
<td>0</td>
</tr>
<tr>
<td>EQT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.45</td>
<td>$5.4</td>
<td>$5.43</td>
<td>$45.00</td>
<td>$70.3K</td>
<td>1.1K</td>
<td>337</td>
</tr>
<tr>
<td>EQT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$50.00</td>
<td>$65.0K</td>
<td>6.0K</td>
<td>249</td>
</tr>
</tbody>
</table>

<h3>About EQT</h3>
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and the transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Following our analysis of the options activities associated with EQT, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of EQT</h3>
<ul>
<li>Trading volume stands at 6,471,656, with EQT's price down by -7.42%, positioned at $46.41.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
<h3>Professional Analyst Ratings for EQT</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $54.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on EQT, which currently sits at a price target of $58. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on EQT with a target price of $66. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on EQT with a target price of $54. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for EQT, targeting a price of $36. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on EQT, which currently sits at a price target of $58. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for EQT, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

EQT Unusual Options Activity For March 06

Investors with a lot of money to spend have taken a bullish stance on SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SITM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for SiTime.
This isn't normal.
The overall sentiment of these big-money traders is split between 61% bullish and 27%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $143,925, and 14 are calls, for a total amount of $1,160,112.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $240.0 for SiTime over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for SiTime's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across SiTime's significant trades, within a strike price range of $150.0 to $240.0, over the past month.
<h3>SiTime Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741287711_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.1</td>
<td>$36.7</td>
<td>$39.0</td>
<td>$150.00</td>
<td>$273.0K</td>
<td align="right">75</td>
<td align="right">70</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$210.00</td>
<td>$169.0K</td>
<td align="right">17</td>
<td align="right">201</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$50.3</td>
<td>$47.0</td>
<td>$49.0</td>
<td>$150.00</td>
<td>$117.6K</td>
<td align="right">75</td>
<td align="right">71</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$4.6</td>
<td>$5.02</td>
<td>$210.00</td>
<td>$102.4K</td>
<td align="right">17</td>
<td align="right">563</td>
</tr>
<tr>
<td>SITM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$190.00</td>
<td>$102.3K</td>
<td align="right">10</td>
<td align="right">787</td>
</tr>
</tbody>
</table>

<h3>About SiTime</h3>
SiTime Corp is a provider of silicon timing systems solutions. The company designs develops and sell silicon timing systems solutions for different industries including automotive, infrastructure, aerospace-defense, consumer, internet of things, consumer and industrials. Its product offerings include Stratum 3E DCOCXOs, Programmable OCXOs, MHz Oscillators, 32.768 kHz Oscillators, Embedded Resonators, Precision MHz Super-TCXOs, and Ruggedized Oscillators. It sells its products around Taiwan, Hong Kong, the United States, and other regions and generates the majority of its revenue from Taiwan.
Following our analysis of the options activities associated with SiTime, we pivot to a closer look at the company's own performance.
<h3>SiTime's Current Market Status</h3>
<ul>
<li>With a volume of 579,712, the price of SITM is down -0.49% at $181.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>What The Experts Say On SiTime</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $256.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $250. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on SiTime with a target price of $250. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on SiTime, which currently sits at a price target of $270. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest SiTime options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

SITM

Behind the Scenes of SiTime's Latest Options Trends

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) with a Buy and maintains $5.75 price target.

HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target

Press Releases

Aurora Readies Customers for Driverless Operations

Aurora to Present at Evercore ISI ADAS, AV & AI Summit

Aurora to Host Third Quarter 2024 Business Review Conference Call on October 30, 2024

Aurora Announces Third Quarter 2024 Results

Aurora Opens Advanced Lidar Research and Testing Facility in Bozeman, Montana

Aurora, Continental, and NVIDIA Partner to Deploy Driverless Trucks at Scale

Aurora to Host Fourth Quarter 2024 Business Review Conference Call on February 12, 2025

Aurora to Present at Canaccord Genuity Sustainability Summit

Aurora Announces Fourth Quarter 2024 Results

Aurora to Present at Cantor Global Technology Conference

Altair Engineering Inc. - Class A Common Stock

Altair Engineering

Ansys

AppFolio

Aspen Technology

Bentley Systems, Incorporated - Class B Common Stock

Bentley Systems

CCC Intelligent Solutions Holdings Inc. - Common Stock

CCC Intelligent Solutions

Confluent

Clearwater Analytics Holdings, Inc. Class A Common Stock

Clearwater Analytics Hldg

Dropbox

DocuSign

Dynatrace

Guidewire Software

HubSpot

Samsara

Klaviyo

Manhattan Associates, Inc. - Common Stock

Manhattan Associates

NICE Ltd - American Depositary Shares each representing one Ordinary Share

NICE

Nutanix

Procore Technologies

Pegasystems

ServiceTitan, Inc. - Class A Common Stock

ServiceTitan

Tyler Technologies

Unity Software

Zoom Communications, Inc. - Class A Common Stock

Zoom Communications

Morgan Stanley

Evercore ISI Group

Cantor Fitzgerald

Canaccord Genuity

Goldman Sachs

WIIM

APPS

BTDR

BTOG

CFLT

CORZ

DOCU

ESTC

HUBS

KVYO

NTNX

NVNI

ORCL

PLTR

PRCH

RBRK

RIOT

TEAM

Shares of software companies are trading lower amid overall market weakness. The industry may be falling amid sympathy with MongoDB after the company issued weak FY26 guidance.

지난주 가장 저조한 성과를 보인 대형주 10종목은 다음과 같다.
<ol>
<li>아카마이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>): 부진한 2025회계연도 가이던스 발표 후 23.01% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/sfm/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.</li>
<li>액손 엔터프라이스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>): 크레이그 할럼 애널리스트 제레미 햄블린(Jeremy Hamblin) 매수에서 보유 의견으로 하향 조정하고 <a href="https://www.benzinga.com/quote/axon/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 625달러로 발표한 후</a> 22.79% 하락했다.</li>
<li>트윌리오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>): 엇갈린 4분기 실적 발표 후 애널리스트들이 <a href="https://www.benzinga.com//node/43742521" target="_blank" rel="noreferrer noopener">목표주가를 수정</a>했고, 이로 인해 22.39% 하락했다.</li>
<li>이팸 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>): 4분기 및 2024회계연도 전체 실적 발표 후 <a href="https://www.benzinga.com//node/43867480" target="_blank" rel="noreferrer noopener">실망스러운 2025년 가이던스</a>를 제시하면서 주가가 21.97% 하락했다.</li>
<li>누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>): 회사의 <a href="https://www.benzinga.com//node/43869101" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a> 발표 후 21.54% 하락했다.</li>
<li>오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>): 미국 소비자 및 경제 우려로 인한 전체 시장 약세로 21.18% 하락했다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 지난 주 21.04% 하락했다. <a href="https://www.benzinga.com//node/43883117" target="_blank" rel="noreferrer noopener">SEC 직원과의 원칙적 합의 발표</a> 후 상승분을 상실했다.</li>
<li>다비타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>): 워런 버핏의 투자 회사 버크셔 해서웨이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)가 다비타의 2% 지분을 매각했다고 발표한 후 19.58% 하락했다. 이 매도 거래는 <a href="https://www.benzinga.com//node/43874883" target="_blank" rel="noreferrer noopener">약 1억 1,600만 달러로 평가되었다.</a></li>
<li>로빈후드 마켓츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 전체 시장 약세로 인해 금융 부문 주식이 하락하면서 19.12% 하락했다.</li>
<li>레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): 지난주 18.81% 하락했다. 파이퍼 샌들러 애널리스트 토마스 챔피언(Thomas Champion)이 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/rddt/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 210달러에서 220달러로 상향 조정</a>했다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 12개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 힘스 앤 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)의 주식은 지난주 42.12% 상승했다. 이는 슈퍼볼 광고 이후의 모멘텀에 힘입어 상승한 것으로 보인다.
2. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43675203" target="_blank" rel="noreferrer noopener">4분기 실적을 발표</a>한 후 41.53% 급등했다.
3. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 회사가 긍정적인 4분기 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/43709891" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 35.77% 상승했다.
4. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 회사가 예비 2분기 재무 결과를 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/43678005" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 32.06% 상승했다.
5. 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식은 회사가 IFLI와의 협력을 발표한 후 29.70% 상승했다. 이는 <a href="https://www.benzinga.com//node/43701711" target="_blank" rel="noreferrer noopener">여포림프종 환자를 위한 표적 치료제 개발</a>을 위한 것이다.
6. 드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주식은 회사가 예상보다 좋은 실적을 발표하고 <a href="https://www.benzinga.com//node/43714236" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 가이던스를 상향 조정</a>한 후 26.51% 상승했다. 캐너코드 제뉴이티의 애널리스트 마이클 그레이엄(Michael Graham)은 매수 등급을 유지하고 <a href="https://www.benzinga.com/quote/dkng/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 54달러에서 60달러로 상향 조정</a>했다.
7. 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 주식은 시장이 <a href="https://www.benzinga.com//node/43723036" target="_blank" rel="noreferrer noopener">18A 공정 노드에 대한 낙관적</a>인 전망을 유지하면서 23.56% 상승했다.
8. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식은 회사가 4분기 실적이 예상보다 좋게 나왔고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43622049" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>한 후 23.33% 상승했다.
9. 더치 브로스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>)의 주식은 회사가 4분기 재무 실적이 예상보다 좋게 나타난 후 22.75% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43704124" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
10. CVS 헬스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)의 주식은 회사가 4분기 실적을 발표하고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43709040" target="_blank" rel="noreferrer noopener">전망을 상향 조정</a>한 후 21.88% 상승했다.
11. 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 주식은 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)이 중국 아이폰 사용자들을 위한 AI 기능 개발 파트너십을 발표한 <a href="https://www.benzinga.com//node/43631776" target="_blank" rel="noreferrer noopener">보고서</a> 이후 20.50% 상승했다.
12. 에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)의 주식은 회사가 긍정적인 4분기 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/43736004" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 19.59% 상승했다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42912519" target="_blank" rel="noreferrer noopener">예상보다 나은</a> 1분기 재무결과를 발표한 후 27.97% 상승했다.
2. 콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)의 주가가 회사가 전력 생산 회사인 칼파인(Calpine Corp.)을 현금 및 주식 <a href="https://www.benzinga.com//node/42916941" target="_blank" rel="noreferrer noopener">164억 달러로 평가된 인수 계약</a>을 발표한 후 25.80% 급등했다.
3. FTAI 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)의 주가가 20.48% 상승했다.
4. TD 시넥스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42915528" target="_blank" rel="noreferrer noopener">예상보다 나은 4분기 재무결과</a>를 발표한 후 15.05% 상승했다.
5. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주가가 회사가 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 및 콘티넨탈 AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CTTAF#OTC">CTTAF</a>)와의 파트너십을 발표한 후 14.59% 상승했다. 이 파트너십은 엔비디아의 <a href="https://www.benzinga.com//node/42841305" target="_blank" rel="noreferrer noopener">차세대 DRIVE Thor SoC</a>를 사용하여 무인 트럭을 확장하는 것이다.
6. 로열티 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42902266" target="_blank" rel="noreferrer noopener">분기 배당금을 인상했다고 발표</a>한 후 14.35% 상승했다.
7. 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주가가 13.75% 상승했다. 회사는 퓨어 스토리지(Pure Storage)와의 협력을 확장하여 고용량, 에너지 효율적인 <a href="https://www.benzinga.com//node/42853369" target="_blank" rel="noreferrer noopener">마이크론 G9 QLC NAND를 사용한 솔루션</a>을 개발한다고 발표했다.
8. 델타항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42912208" target="_blank" rel="noreferrer noopener">예상보다 나은 실적을 발표하고 2025년 가이던스를 발표</a>한 후 13.34% 상승했다.
9. 인트라셀룰라 테라피(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)의 주가가 12.62% 상승했다. 회사는 산도즈(Sandoz)와 화해 계약을 체결하고 CAPLYTA Patent와 관련된 특허 소송을 해결했다.
10 유나이티드 에어라인 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) 주가가 델타 항공와 동반 상승하여 12.24% 급등했다. 델타 항공는 <a href="https://www.benzinga.com//node/42919651" target="_blank" rel="noreferrer noopener">4분기 재무결과가 좋다고 발표</a>한 후 상승했다.
사진 출처: VanderWolf via Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 9개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주가는 20.93% 급락했다. 공매도 업체인 힌덴버그 리서치의 비판적인 보고서는 <a href="https://www.benzinga.com//node/42784518" target="_blank" rel="noreferrer noopener">Carvana의 회복을 &#8220;신기루&#8221;</a>로 묘사하면서 약세 정서를 강화했다.
2. 소파이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)의 주식은 키프, 브루옛 &amp; 우즈(Keefe, Bruyette and Woods)가 <a href="https://www.benzinga.com/quote/SOfi/analyst-ratings" target="_blank" rel="noreferrer noopener">시장 수행에서 언더퍼폼으로 하향 조정</a>한 후 10.60% 하락했다.
3. 얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주식은 10.40% 하락했다.
4. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 회사가 4분기 <a href="https://www.benzinga.com//node/42766117" target="_blank" rel="noreferrer noopener">생산 및 인도 수치</a>를 발표한 후 9.62% 급락했다. 애널리스트들은 주식에 대한 <a href="https://www.benzinga.com//node/42786667" target="_blank" rel="noreferrer noopener">가격 예측</a>을 수정했다.
5. 킨세일 캐피털 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>)의 주식은 JP 모건이 주식의 목표 가격을 <a href="https://www.benzinga.com/quote/knsl/analyst-ratings" target="_blank" rel="noreferrer noopener">$415에서 $412로 하향 조정</a>한 후 9.45% 하락했다.
6. 브라운 포먼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>)의 주식은 미국 총기 건강 책임자 머시가 알코올 소비가 암 위험을 증가시킬 수 있다는 경고를 발표한 후 8.20% 하락했다.
7. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 씨티그룹이 주식의 가격 예측을 <a href="https://www.benzinga.com/quote/tcom/analyst-ratings" target="_blank" rel="noreferrer noopener">$73에서 $78로 상향 조정</a>한 후 7.47% 하락했다.
8. 포멘토 이코노미코 멕시카노 S.A.B. de C.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>)의 주식은 미국 공중보건국장인 비벡 머시(Vivek Murthy)가 알코올 소비와 관련된 암 위험 증가에 대해 경고한 후 7.47% 하락했다.
9. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주식은 9.47% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%AA%A8%EB%B9%8C%EC%95%84%EC%9D%B4-%EB%B0%8F-arm%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">리비안, 모빌아이 및 Arm은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 30일-1월 3일)</a></li>
</ul>
이미지 출처: Tesla
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Aurora Innovation

뉴스

에 대한 최신 뉴스 Aurora Innovation (NASDAQ:AUR) 주식

월요일, 2월 24, 2025

일요일, 2월 16, 2025

일요일, 1월 12, 2025

일요일, 1월 05, 2025

토요일, 1월 04, 2025

일요일, 12월 08, 2024

목요일, 11월 28, 2024

토요일, 10월 26, 2024

월요일, 9월 16, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌